Pamela Noldner leads the Cell Therapy Process Development team at the Marcus Center for Cellular Cures (MC3) at the Duke School of Medicine. In this role, she oversees the development, optimization, and scaleup of GMPcompliant manufacturing processes for both allogeneic and autologous cellbased therapies.Over the past ten years, her work has covered the process development from initial cell sourcing through final formulation and cryopreservation. She has helped build and implement closedsystem and automated workflows, including largescale bioreactor approaches, and has supported product characterization through ELISAs and the development of potency assays. Her team works across multiple cell types, including MSCs, TILs, CAR T cells, γδ T cells, macrophages, and NK cells, drawing on extensive experience with cordblood–derived cultures.Pamela has designed and authored IND amendment studies, authored GMP documentation such as SOPs and batch records, and led technical transfers to manufacturing and quality control groups. She also manages collaborations with academic labs and biotechnology partners.